Category: Drug Therapy
-
RougeTx Launches with HHT as Lead Therapeutic Program
RougeTx, a new biotechnology company focused on vascular disease, has launched with $58 million in Series A financing to advance RTX-001, an investigational treatment…
-
Tectonic Reports Early Safety Data for TX2100: What It Means for HHT Research
The hereditary hemorrhagic telangiectasia (HHT) treatment landscape continues to grow. On September 29, Tectonic Therapeutic announced early clinical results for TX2100, an investigational therapy…
-
A History of Pazopanib
There are no FDA-approved therapeutics for the treatment of HHT. Cure HHT sought to change that. In many ways, the history of pazopanib is…
-
A major milestone for HHT treatment!
I am reaching out to share the news of a truly momentous milestone for both our organization and our community; the Pazopanib clinical trial…
-
Pazopanib Clinical Trial: Q&A
The Pazopanib clinical trial has launched, and the road to reach this breakthrough milestone has been more involved and hard-fought than many may realize.…